JP2008542414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542414A5 JP2008542414A5 JP2008515121A JP2008515121A JP2008542414A5 JP 2008542414 A5 JP2008542414 A5 JP 2008542414A5 JP 2008515121 A JP2008515121 A JP 2008515121A JP 2008515121 A JP2008515121 A JP 2008515121A JP 2008542414 A5 JP2008542414 A5 JP 2008542414A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- drugs
- disease
- cocaine
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 32
- 230000002265 prevention Effects 0.000 claims description 18
- 208000011117 substance-related disease Diseases 0.000 claims description 18
- 208000019695 Migraine disease Diseases 0.000 claims description 16
- 206010027599 migraine Diseases 0.000 claims description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 16
- 208000011580 syndromic disease Diseases 0.000 claims description 16
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 206010013663 drug dependence Diseases 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 206010013654 Drug abuse Diseases 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 claims description 8
- 208000032841 Bulimia Diseases 0.000 claims description 8
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 8
- 206010006895 Cachexia Diseases 0.000 claims description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 8
- 206010011224 Cough Diseases 0.000 claims description 8
- 206010012735 Diarrhoea Diseases 0.000 claims description 8
- 208000007882 Gastritis Diseases 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 208000007101 Muscle Cramp Diseases 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 206010033664 Panic attack Diseases 0.000 claims description 8
- 208000004880 Polyuria Diseases 0.000 claims description 8
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 8
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 8
- 208000009205 Tinnitus Diseases 0.000 claims description 8
- 206010046543 Urinary incontinence Diseases 0.000 claims description 8
- 208000022531 anorexia Diseases 0.000 claims description 8
- 230000001598 anti-natriuretic effect Effects 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 210000000748 cardiovascular system Anatomy 0.000 claims description 8
- 206010008118 cerebral infarction Diseases 0.000 claims description 8
- 230000007278 cognition impairment Effects 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 206010061428 decreased appetite Diseases 0.000 claims description 8
- 230000006735 deficit Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000035619 diuresis Effects 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 230000037406 food intake Effects 0.000 claims description 8
- 235000012631 food intake Nutrition 0.000 claims description 8
- 201000005917 gastric ulcer Diseases 0.000 claims description 8
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 238000002690 local anesthesia Methods 0.000 claims description 8
- 206010027175 memory impairment Diseases 0.000 claims description 8
- 230000008450 motivation Effects 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 201000003631 narcolepsy Diseases 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 229940005483 opioid analgesics Drugs 0.000 claims description 8
- 208000019906 panic disease Diseases 0.000 claims description 8
- 230000001314 paroxysmal effect Effects 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 231100000886 tinnitus Toxicity 0.000 claims description 8
- 208000028698 Cognitive impairment Diseases 0.000 claims description 7
- 206010010904 Convulsion Diseases 0.000 claims description 7
- 230000036461 convulsion Effects 0.000 claims description 7
- 230000035807 sensation Effects 0.000 claims description 7
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 201000001272 cocaine abuse Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000011282 treatment Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- NLMVYUBGWZWUGB-UHFFFAOYSA-N 1,2-benzoxazol-3-amine Chemical class C1=CC=C2C(N)=NOC2=C1 NLMVYUBGWZWUGB-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005026194A DE102005026194A1 (de) | 2005-06-06 | 2005-06-06 | Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln |
| PCT/EP2006/005356 WO2006131296A1 (de) | 2005-06-06 | 2006-06-06 | Substituierte n-benzo [d] isoxazol-3-yl-amin-derivative als inhibitoren von mglur5, serotonin- (5-ht) und noradrenalin rezeptoren und deren verwendung zur herstellung von arzneimitteln |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008542414A JP2008542414A (ja) | 2008-11-27 |
| JP2008542414A5 true JP2008542414A5 (enExample) | 2012-11-22 |
Family
ID=36792815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515121A Ceased JP2008542414A (ja) | 2005-06-06 | 2006-06-06 | ＭＧｌＵＲ５、セロトニン（５−ＨＴ）及びノルアドレナリン受容体の阻害剤としての置換されたＮ−ベンゾ［Ｄ］イソオキサゾール−３−イル−アミン誘導体及び医薬の製造へのその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080312301A1 (enExample) |
| EP (1) | EP1893589B1 (enExample) |
| JP (1) | JP2008542414A (enExample) |
| AT (1) | ATE524451T1 (enExample) |
| CA (1) | CA2610373A1 (enExample) |
| CY (1) | CY1112449T1 (enExample) |
| DE (1) | DE102005026194A1 (enExample) |
| DK (1) | DK1893589T3 (enExample) |
| ES (1) | ES2373684T3 (enExample) |
| PL (1) | PL1893589T3 (enExample) |
| PT (1) | PT1893589E (enExample) |
| SI (1) | SI1893589T1 (enExample) |
| WO (1) | WO2006131296A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005038947A1 (de) * | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| WO2009012312A1 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| KR102746352B1 (ko) | 2014-08-13 | 2024-12-24 | 오클랜드 유니서비시즈 리미티드 | 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 |
| AU2016312848A1 (en) * | 2015-08-27 | 2018-03-29 | Auckland Uniservices Limited | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy |
| US20190099404A1 (en) * | 2016-03-16 | 2019-04-04 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
| CN110117278B (zh) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 |
| US20230250088A1 (en) * | 2020-07-15 | 2023-08-10 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| JP7783252B2 (ja) * | 2020-07-29 | 2025-12-09 | ヴィヴォゾン・インコーポレイテッド | ｍＧｌｕＲ５及び５－ＨＴ２Ａ受容体の二重調節剤及びその使用 |
| TW202317087A (zh) | 2021-08-10 | 2023-05-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關病況之化合物及組合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5721377A (en) * | 1980-07-11 | 1982-02-04 | Shionogi & Co Ltd | 3-substituted-1,2-benzisoxazole derivative |
| US4322429A (en) * | 1980-09-16 | 1982-03-30 | Eli Lilly And Company | Isoxazolylbenzamides as insecticides |
| FR2654104B1 (fr) * | 1989-11-07 | 1992-01-03 | Adir | Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2701026B1 (fr) * | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| AU2002323474B2 (en) * | 2001-09-13 | 2006-10-05 | Synta Pharmaceuticals Corp | 3-glyoxlylamideindoles for treating cancer |
| KR100789567B1 (ko) * | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
| GB0319150D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| WO2005070891A2 (en) * | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
| US20070197610A1 (en) * | 2004-03-16 | 2007-08-23 | Janssen Pharmaceutica N.V. | Benzisoxazoles |
| US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
-
2005
- 2005-06-06 DE DE102005026194A patent/DE102005026194A1/de not_active Withdrawn
-
2006
- 2006-06-06 JP JP2008515121A patent/JP2008542414A/ja not_active Ceased
- 2006-06-06 DK DK06761974.2T patent/DK1893589T3/da active
- 2006-06-06 PL PL06761974T patent/PL1893589T3/pl unknown
- 2006-06-06 WO PCT/EP2006/005356 patent/WO2006131296A1/de not_active Ceased
- 2006-06-06 SI SI200631193T patent/SI1893589T1/sl unknown
- 2006-06-06 ES ES06761974T patent/ES2373684T3/es active Active
- 2006-06-06 EP EP06761974A patent/EP1893589B1/de not_active Not-in-force
- 2006-06-06 AT AT06761974T patent/ATE524451T1/de active
- 2006-06-06 PT PT06761974T patent/PT1893589E/pt unknown
- 2006-06-06 CA CA002610373A patent/CA2610373A1/en not_active Abandoned
- 2006-06-06 US US11/916,613 patent/US20080312301A1/en not_active Abandoned
-
2011
- 2011-12-13 CY CY20111101238T patent/CY1112449T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526061A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| JP2008542414A5 (enExample) | ||
| JP2005531557A5 (enExample) | ||
| KR960007568A (ko) | 트리사이클릭 피라졸 유도체 | |
| JP2010535801A5 (enExample) | ||
| WO2007016353A3 (en) | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists | |
| JP2007516941A5 (enExample) | ||
| CA2719749A1 (en) | Methods for treating disorders using nmda nr2b-subtype selective antagonist | |
| JP2011527333A5 (enExample) | ||
| TW200507847A (en) | Method for enhancing cognition using ziprasidone | |
| RU2009135016A (ru) | Твердые формы, содержащие (-)-о-десметилвенлафаксин, и их применения | |
| JP2012508275A5 (enExample) | ||
| JP2007518763A (ja) | 下部尿路障害の処置に有用なα−アミノアミド誘導体 | |
| JP5319920B2 (ja) | ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用 | |
| WO2006019886A3 (en) | Pyrrolo(oxo)isoquinolines as 5ht ligands | |
| KR20150091163A (ko) | 아미노사이클로부탄 유도체들, 이들을 제조하는 방법 및 약물들로서 그들의 용도 | |
| TW200613255A (en) | Therapeutic diphenyl ether ligands | |
| JP2008512405A5 (enExample) | ||
| CN1160347A (zh) | 吲哚衍生物在治疗皮肤病、外周神经病、关节炎、头痛、口面疼痛、过敏或慢性导气管阻塞病、青光眼及眼部炎症中的应用 | |
| JP5553955B2 (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ | |
| JP2007505156A5 (enExample) | ||
| DK1381614T3 (da) | Antidepressive azaheterocyclylmethylderivater af 2,3-dihydro-1,4-dioxino[2,3-f]quinoxalin | |
| JP2007531750A5 (enExample) |